

APT™ FORMULATION PROVEN TO COMBAT MULTI-DRUG RESISTANT CANDIDA AURIS – AN URGENT GLOBAL HEALTHCARE THREAT

An opportunity to stop the Candida auris spread across global healthcare with effective skin decolonization.

ROCKWALL, TEXAS, UNITED STATES, March 29, 2023 /EINPresswire.com/ -- The Centers for Disease Control (CDC) and World Health Organization have "sounded the alarm" on [Candida auris \(C. auris\)](#) – a multi-drug resistant fungus that has a 60% mortality rate if it enters the bloodstream of patients. The CDC has noted that cases of C. auris have jumped 200% since 2019.

This is of particular concern because unlike most fungi, C. auris is easily spread by contact from person to person. Its rapidly developing resistance to current therapies makes an effective prevention strategy an even more important focus across all types of healthcare organizations.

“

The APT™ formulation with Chlorhexidine may provide safe/easy method to decolonize the skin of healthcare workers and patients, thus interrupting skin colonization of the dangerous Candida auris”

Dr. Mahmoud Ghannoum

APT, LLC has a validated formulation incorporating our Advanced Performance Technology™ and Chlorhexidine to create, what we describe as Chlorhexidine Next Gen™. APT, LLC has worked for 3 years to develop a skin decolonizing formula to remove the Candida auris threat from patients and healthcare workers.

Chlorhexidine is a well-known and accepted topical skin cleanser across the global healthcare continuum. Empowering the Chlorhexidine product with our proprietary formulation has now created a highly effective tool for healthcare providers to start reducing the rapid

spread of Candida auris in hospitals, nursing homes, skilled nursing facilities and long-term care. Skin decolonization (removing C. auris from skin surfaces) is the key to stopping this spreading



The screenshot shows a Medscape news article from Friday, March 24, 2023. The article is titled "Cases of Potentially Deadly Fungus Jump 200%: CDC" and is categorized under "NEWS & PERSPECTIVE". The author is Lisa O'Mary, dated March 21, 2023. The article text states: "Cases of a potentially deadly and increasingly treatment-resistant fungus called *Candida auris* have skyrocketed 200% since 2019, prompting the CDC to issue a warning to health care facilities about the rising threat. C. auris is a yeast that spreads easily by touching it on a surface like a countertop." Below the text, there is a comment icon with the number 5 and a thumbs-up icon with the number 82. A sub-headline at the bottom of the screenshot reads "CDC noted increases in C. auris cases since 2019".

global healthcare threat.

APT, LLC has worked with world-renowned specialists and fungal disease experts, most notably Dr. Mahmoud Ghannoum, who at the CDC's request, tested the most resistant strains of *Candida auris* directly from their lab, with our Chlorhexidine Next Gen formulation. Test results demonstrated the high efficacy against resistant *C. auris*.

[Peer Reviewed Published Manuscript](#): American Journal of Infection Control, Nov 2022

Advanced Performance Technology, LLC is a Texas and Indiana based pharmaceutical IP company that has created new solutions for areas of patient care using our APT based formulations. Its products have been used to treat wounds, resistant bacterial infections, resistant fungal infections, burns and other conditions. Our focus is to out-license our formulations to industry partners to manage challenges across the global healthcare system.

Brian Huber

Patient Focused Tele-Health, LLC

+1 800-918-7534

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/624778278>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.